The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.
Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills ...
An AI-enabled wearable sensor with vibratory feedback significantly reduces nocturnal scratching in atopic dermatitis, ...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...
3d
Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...
itchy rash. Dermatitis refers to a number of skin conditions driven by inflammation, including atopic dermatitis (a type of eczema) and contact dermatitis. Dermatitis isn’t always curable ...
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback